The National Association of REALTORS® and Move, Inc., a company that works with its subsidiaries to operate an online network of Websites, announced that the lead of REALTOR.com as the world’s largest online website for real estate listings has been extended with the launch of the REALTOR.com International website.
The new site, www.REALTOR.com/International, delivers millions of real estate listings to buyers around the world. At its launch, REALTOR.com International will feature residential real estate listings from Croatia, Bulgaria, France, Spain, Brazil, Portugal, Serbia, Romania, Slovakia, and Italy. The REALTOR.com International site can be accessed from the REALTOR.com homepage as well.
In the last three months, almost 2.6 million International visitors have searched for U.S. real estate on REALTOR.com. The top five countries where the searches have originated are from the United Kingdom, Canada, Australia, Germany, and India.
“Increasingly, more and more Realtors are working with international clients who want to buy property in the U.S. and the new REALTOR.com International web site will not only allow Realtors to offer their expertise and knowledge to a broader audience, but will also bring buyers and sellers together across the globe,” said NAR President Ron Phipps, broker-president of Phipps Realty in Warwick, Rhode Island. “Foreign buyers understand the value of owning a home in the U.S. and can rely on a Realtor because of their global perspective and understanding of different cultures and real estate practices. This collaboration with Move is just one of many ways Realtors can expand and grow their business globally.”
To aid international and foreign-born buyers as they search for U.S. residential real estate, the new REALTOR.com International search experience offers more enhanced translation options in 11 languages, which include Dutch, English, Chinese, French, German, Italian, Korean, Portuguese, Russian, Spanish, and Japanese. The site also includes an easy-to-use currency and dimension converters, which are available on all pages.
“The U.S. continues to be a top destination for international buyers from all over the world, and REALTOR.com remains a natural choice for international buyers because we offer the largest, freshest and most accurate collection of property listings available online,” said REALTOR.com President, Errol Samuelson. “In recent years, foreign buyers have increasingly become interested in owning real estate in the United States. Like millions of U.S. consumers, they trust the REALTOR.com brand to help them connect with Realtors and find the property that’s right for their needs. Opening up the world of real estate on REALTOR.com to include an international search experience is a natural evolution of our offerings at Move. We’re very excited to help hundreds of thousands of Realtors grow their businesses beyond U.S. borders as they connect with international buyers.”
NAR’s 2011 Profile of International Home Buying Activity has reported that the U.S. remains a top destination for foreign buyers with international purchases soaring to $16 billion in the last year. In accordance to the survey, total residential international sales last year in the U.S. amounted to $82 billion. Total international sales were split evenly between recent immigrants and non-resident foreigners.
International buyers of U.S. residential real estate came from 70 countries. The top five (Mexico, Canada, China, UK, and India) made up 53 percent of all transactions from March of 2010 to March 2011. Most states in the U.S. had at least one international transaction, while Florida, California, Texas, and Arizona made up 58 percent of all U.S. residential transactions that were completed by International buyers. The convenience of air transportation, climate and location, and the proximity to their homeland are the most important factors for international buyers.
Presentations for international content providers who are interested in learning how to feed in their listing to REALTOR.com International will take place at the 2011 Realtors® Conference and Expo in Anaheim, California, from November 11th through the 14th.
For more information on Move, Inc., visit www.move.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Thursday, November 3, 2011
Wednesday, November 2, 2011
Commtouch (CTCH) Posts Q3 Financial Results and Highlights, Reaffirms Full-year Guidance
Commtouch, a leading cloud-based Internet security provider, today announced its 2011 third-quarter results and business highlights for the three months ended September 30, 2011.
The company reported third-quarter revenue at $5.9 million, a 27 percent increase compared to $4.6 million in the third quarter of 2010.
Net income for the third quarter of 2011 decreased 16 percent to $887,000, or $0.04 per diluted share, compared to $1.1 million, or $0.05 per diluted share, reported for the third quarter of 2010.
Commtouch’s deferred revenues (long-term and short-term) as of September 30, 2011, totaled $4.1 million compared to $3.5 million in deferred revenues as of June 30, 2011.
Operating cash flow for the third quarter of 2011 was $1.5 million compared to $1.6 million in the third quarter of 2010.
As of September 30, 2011, the company had cash at $17.6 million compared to $16.1 million as of June 30, 2011.
“I am happy to report another strong quarter with consistent revenue growth and improvement of our operating and net margins that led to higher profitability,” Ron Ela, Commtouch CFO stated in the press release. “This steady financial growth remains a solid basis from which to implement our future plans.”
The company noted growing demand for its products in the third quarter of 2011; a new agreement with a communications leader for which Commtouch will provide its antivirus solution; expanding contracts with existing contracts; and the launch of version eight of its e-mail and Web security solution platform.
Commtouch reaffirms its full-year 2011 guidance, expecting revenue and net income to be midrange in previous guidance of full-year revenues between $22.5 million and $23.5 million, and net income between $6.2 million and $6.7 million.
For more information visit www.commtouch.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The company reported third-quarter revenue at $5.9 million, a 27 percent increase compared to $4.6 million in the third quarter of 2010.
Net income for the third quarter of 2011 decreased 16 percent to $887,000, or $0.04 per diluted share, compared to $1.1 million, or $0.05 per diluted share, reported for the third quarter of 2010.
Commtouch’s deferred revenues (long-term and short-term) as of September 30, 2011, totaled $4.1 million compared to $3.5 million in deferred revenues as of June 30, 2011.
Operating cash flow for the third quarter of 2011 was $1.5 million compared to $1.6 million in the third quarter of 2010.
As of September 30, 2011, the company had cash at $17.6 million compared to $16.1 million as of June 30, 2011.
“I am happy to report another strong quarter with consistent revenue growth and improvement of our operating and net margins that led to higher profitability,” Ron Ela, Commtouch CFO stated in the press release. “This steady financial growth remains a solid basis from which to implement our future plans.”
The company noted growing demand for its products in the third quarter of 2011; a new agreement with a communications leader for which Commtouch will provide its antivirus solution; expanding contracts with existing contracts; and the launch of version eight of its e-mail and Web security solution platform.
Commtouch reaffirms its full-year 2011 guidance, expecting revenue and net income to be midrange in previous guidance of full-year revenues between $22.5 million and $23.5 million, and net income between $6.2 million and $6.7 million.
For more information visit www.commtouch.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
BioSante Pharmaceuticals, Inc. (BPAX) is “One to Watch”
BioSante Pharmaceuticals, Inc. has a strong portfolio of specialty products/candidates in the areas of sexual health and oncology. Employing a shrewd, collaborative framework of strategic partners/licensees, BioSante’s experienced development team has grown extremely proficient at identifying valuable opportunities and then leveraging the extended resources of the company’s partner network in order to progress rapidly from candidate towards a successfully branded product.
Lead products like LibiGel® (Phase III), a once-a-day transdermal gel engineered to absorb quickly into the skin after it is rubbed on the upper arm, show tremendous potential in targeted markets. In this case where women suffering from HSDD (hypoactive sexual desire disorder, characterized by lowered sex drive) benefit both from reduced skin reaction customary in other transdermal delivery solutions and the ability of the proprietary formulation of testosterone to alleviate HSDD symptoms, increasing sexual desire and satisfaction, while lowering sexual distress.
BioSante’s Elestrin™ gel, marketed in the US by BPAX licensee Azur Pharma, is an ultra-low dose prescription formulation of estrogen (estradiol) for hot flashes associated with menopause and engineered along emerging guidelines for such treatments from estrogen therapy/gynecology experts at the FDA, NAMS (North American Menopause Society) and ACOG (American College of Obstetricians and Gynecologists), who recommend the lowest dosage possible for the shortest interval. Fast-drying and colorless, this clear gel product contains a form of estradiol identical to that in the body; a single dose rubbed into the upper arm or shoulder is enough to treat moderate-to-severe hot flashes.
Rounding out the BioSante portfolio are three other offerings. The Pill-Plus™, an oral contraceptive that is currently under development, featuring a triple component formulation which adds an androgen (similar to testosterone) to the typical estrogen/progestin combination and has shown results in trials of increased sexual activity. Bio-T-Gel™, a once-daily transdermal formulation of testosterone engineered to treat male hypogonadism, typically characterized by impotence, osteoporosis, and weakness of the muscles, in addition to a general lack of sex drive. And finally, a series of ongoing cancer vaccine work with multiple offerings in various Phase I and II clinical trials, work that has been supercharged by the 2010 FDA approval of Provenge for the treatment of prostate cancer.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Lead products like LibiGel® (Phase III), a once-a-day transdermal gel engineered to absorb quickly into the skin after it is rubbed on the upper arm, show tremendous potential in targeted markets. In this case where women suffering from HSDD (hypoactive sexual desire disorder, characterized by lowered sex drive) benefit both from reduced skin reaction customary in other transdermal delivery solutions and the ability of the proprietary formulation of testosterone to alleviate HSDD symptoms, increasing sexual desire and satisfaction, while lowering sexual distress.
BioSante’s Elestrin™ gel, marketed in the US by BPAX licensee Azur Pharma, is an ultra-low dose prescription formulation of estrogen (estradiol) for hot flashes associated with menopause and engineered along emerging guidelines for such treatments from estrogen therapy/gynecology experts at the FDA, NAMS (North American Menopause Society) and ACOG (American College of Obstetricians and Gynecologists), who recommend the lowest dosage possible for the shortest interval. Fast-drying and colorless, this clear gel product contains a form of estradiol identical to that in the body; a single dose rubbed into the upper arm or shoulder is enough to treat moderate-to-severe hot flashes.
Rounding out the BioSante portfolio are three other offerings. The Pill-Plus™, an oral contraceptive that is currently under development, featuring a triple component formulation which adds an androgen (similar to testosterone) to the typical estrogen/progestin combination and has shown results in trials of increased sexual activity. Bio-T-Gel™, a once-daily transdermal formulation of testosterone engineered to treat male hypogonadism, typically characterized by impotence, osteoporosis, and weakness of the muscles, in addition to a general lack of sex drive. And finally, a series of ongoing cancer vaccine work with multiple offerings in various Phase I and II clinical trials, work that has been supercharged by the 2010 FDA approval of Provenge for the treatment of prostate cancer.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Tuesday, November 1, 2011
Wave Systems Corp. (WAVX) Signs Strategic Distribution Agreement with Ingram Micro (IM)
Wave Systems Corp., a leading provider of client and server software for hardware-based digital security that enables organizations to know who is connecting to their IT infrastructure, protect corporate data, and strengthen boundaries of their networks, today announced a strategic distribution agreement with Ingram Micro (NYSE: IM) starting November 1. The deal allows for the offering of Wave’s EMBASSY security software to more resellers around the world via Ingram’s network of customers for the managing of hardware-based data protection and authentication. Ingram Micro serves more than 150 countries on six continents and maintains the world’s most comprehensive portfolio of IT products and services.
“We are thrilled to have the opportunity to work with such an established global leader as Ingram Micro and look forward to offering our management tools for trusted computing around the world,” said Brian Berger, Executive Vice President of Marketing and Sales, Wave Systems in a press release Tuesday.
Wave’s core products use a highly secure cryptographic support system known as the Trusted Platform Module (TPM) to generate, store and process keys used to encrypt information and harden identities. Wave’s comprehensive suite of products leverages these capabilities to allow an organization to implement a safer, more trusted computing environment. In fact, Wave’s flagship software offering, EMBASSY® Trust Suite, comes installed on every business-class laptop computer shipping from Dell.
“This agreement allows us to offer Wave’s comprehensive management for data protection and authentication to more IT resellers around the world,” said Eric Kohl, Director, Ingram Micro Advanced Technology Division, in the Tuesday press announcement. ” Ingram Micro is very excited to offer Wave’s robust management tools for embedded hardware security — SEDs for protecting data and TPMs for strengthening authentication — to its network of partners and our partners’ customers.”
Ingram Micro is the world’s largest technology distributor and a leading technology, sales, marketing and logistics company for the IT industry worldwide. Since 1979 Ingram Micro has connected technology solution providers with vendors, bringing the latest products and services to the market.
Wave reports that its customers include the world’s largest chemical company, one of the largest automotive manufacturers, healthcare systems, financial institutions and government agencies.
For more Information about Wave and the Embassy Suite of products, please visit www.wave.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
“We are thrilled to have the opportunity to work with such an established global leader as Ingram Micro and look forward to offering our management tools for trusted computing around the world,” said Brian Berger, Executive Vice President of Marketing and Sales, Wave Systems in a press release Tuesday.
Wave’s core products use a highly secure cryptographic support system known as the Trusted Platform Module (TPM) to generate, store and process keys used to encrypt information and harden identities. Wave’s comprehensive suite of products leverages these capabilities to allow an organization to implement a safer, more trusted computing environment. In fact, Wave’s flagship software offering, EMBASSY® Trust Suite, comes installed on every business-class laptop computer shipping from Dell.
“This agreement allows us to offer Wave’s comprehensive management for data protection and authentication to more IT resellers around the world,” said Eric Kohl, Director, Ingram Micro Advanced Technology Division, in the Tuesday press announcement. ” Ingram Micro is very excited to offer Wave’s robust management tools for embedded hardware security — SEDs for protecting data and TPMs for strengthening authentication — to its network of partners and our partners’ customers.”
Ingram Micro is the world’s largest technology distributor and a leading technology, sales, marketing and logistics company for the IT industry worldwide. Since 1979 Ingram Micro has connected technology solution providers with vendors, bringing the latest products and services to the market.
Wave reports that its customers include the world’s largest chemical company, one of the largest automotive manufacturers, healthcare systems, financial institutions and government agencies.
For more Information about Wave and the Embassy Suite of products, please visit www.wave.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
VistaGen Therapeutics, Inc. (VSTA) Means New Hope for Old Drugs
It makes no difference how effective a new drug candidate is in the fight against cancer or other deadly disease. It also makes no difference how much effort, time, or money has gone into the development and evaluation of such a promising drug. It doesn’t even matter how many lives can be saved by its use. In fact, despite their efficacy, most of these drugs have a very good chance of simply being shelved. It happens all the time, resulting in the loss of potentially life-saving therapies, along with countless millions of dollars in wasted research.
These critically needed drugs are oftentimes lost due to toxicity issues that go undiscovered until late in the development process, after much of the work has been done and most of the money has been spent. For example, cardiotoxicity alone has been implicated in nearly 30% of drug withdrawals. Currently, such toxicity is frequently uncovered late in the game, during human clinical trials, or sometimes even after FDA approval. The human and financial toll of such late withdrawals is enormous, but could be avoided given a more efficient and accurate way of testing drugs earlier in development.
VistaGen Therapeutics has discovered a powerful new approach to toxicity testing that has been shown to be far superior to animal tests or other traditional early testing methods. The concept is based upon the use of human pluripotent stem cells that can be engineered to effectively duplicate the human cellular environment, allowing tests of unmatched precision. Potential toxicity is discovered early and relatively inexpensively, allowing non-toxic drug variations to be developed. In addition, previous drug candidates, shelved for toxicity reasons, can now be cost effectively reconsidered for potential variants, opening the door to new life-saving drugs and all of the associated profits.
For additional information, visit the company’s website at www.VistaGen.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
These critically needed drugs are oftentimes lost due to toxicity issues that go undiscovered until late in the development process, after much of the work has been done and most of the money has been spent. For example, cardiotoxicity alone has been implicated in nearly 30% of drug withdrawals. Currently, such toxicity is frequently uncovered late in the game, during human clinical trials, or sometimes even after FDA approval. The human and financial toll of such late withdrawals is enormous, but could be avoided given a more efficient and accurate way of testing drugs earlier in development.
VistaGen Therapeutics has discovered a powerful new approach to toxicity testing that has been shown to be far superior to animal tests or other traditional early testing methods. The concept is based upon the use of human pluripotent stem cells that can be engineered to effectively duplicate the human cellular environment, allowing tests of unmatched precision. Potential toxicity is discovered early and relatively inexpensively, allowing non-toxic drug variations to be developed. In addition, previous drug candidates, shelved for toxicity reasons, can now be cost effectively reconsidered for potential variants, opening the door to new life-saving drugs and all of the associated profits.
For additional information, visit the company’s website at www.VistaGen.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Vertex Energy, Inc. (VTNR) Reports Improvements, Record Revenue for Q3 2011
Vertex Energy, Inc., a leader in the aggregation, re-refining and processing of distressed petroleum streams such as used oil, transmix, fuel oils and off-specification commercial chemical products, today posted its financial results for the third quarter and nine months ended September 30, 2011.
“The third quarter of this year, like the first and second quarters of 2011, illustrated the improvements we’ve made in virtually every area of our business compared to last year. As we continue to aggregate and process greater volumes of product we improve our ability to drive revenue as we strengthen our position within the used oil market,” Benjamin P. Cowart, CEO of Vertex stated in the press release.
The company reported consolidated revenue of $30.3 million, a 128 percent increase over third quarter 2010 revenue of $13.2 million. For the first nine months of 2011, the company reported revenue of $78.4 million, an 85 percent increase over the first nine months of 2010.
Gross profit for the third quarter increased 148 percent to $2.03 million compared to $818,607 reported in the comparable quarter of 2010. Gross profit for the first nine months of the year increased 146 percent to $6.77 million.
Vertex’s third-quarter 2011 net income increased 393 percent to $1.03 million, or $0.06 per fully diluted share, compared to third quarter 2010 net income of $208,580, or $0.02 per fully diluted share. Net income for the first nine months of 2011 improved to $3.64 million, or $0.25 per fully diluted share, a 378 percent increase over the first nine months of 2010.
The company’s overall quarterly sales volumes increased 36 percent compared to third quarter 2010; volumes for the first nine months of 2011 increased 21 percent compared to the same period last year.
Cowart said the company will continue to expand its used oil aggregation footprint, overall sales volume, and its patent-pending Thermal-Chemical Extraction Process (TCEP) throughput rates compared to last year.
“The third quarter of 2011 represents our highest revenue quarter yet. TCEP, which has grown in its contribution to Vertex’s top line over time, continues to run effectively even while we are still implementing improvements to the process,” Cowart stated. “For the remainder of 2011, we expect to continue to exploit our competitive advantage in the combination of used oil aggregation and TCEP operations, while also evaluating potential acquisitions that could enhance our overall competitive positioning within the industry.”
For more information visit www.vertexenergy.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
“The third quarter of this year, like the first and second quarters of 2011, illustrated the improvements we’ve made in virtually every area of our business compared to last year. As we continue to aggregate and process greater volumes of product we improve our ability to drive revenue as we strengthen our position within the used oil market,” Benjamin P. Cowart, CEO of Vertex stated in the press release.
The company reported consolidated revenue of $30.3 million, a 128 percent increase over third quarter 2010 revenue of $13.2 million. For the first nine months of 2011, the company reported revenue of $78.4 million, an 85 percent increase over the first nine months of 2010.
Gross profit for the third quarter increased 148 percent to $2.03 million compared to $818,607 reported in the comparable quarter of 2010. Gross profit for the first nine months of the year increased 146 percent to $6.77 million.
Vertex’s third-quarter 2011 net income increased 393 percent to $1.03 million, or $0.06 per fully diluted share, compared to third quarter 2010 net income of $208,580, or $0.02 per fully diluted share. Net income for the first nine months of 2011 improved to $3.64 million, or $0.25 per fully diluted share, a 378 percent increase over the first nine months of 2010.
The company’s overall quarterly sales volumes increased 36 percent compared to third quarter 2010; volumes for the first nine months of 2011 increased 21 percent compared to the same period last year.
Cowart said the company will continue to expand its used oil aggregation footprint, overall sales volume, and its patent-pending Thermal-Chemical Extraction Process (TCEP) throughput rates compared to last year.
“The third quarter of 2011 represents our highest revenue quarter yet. TCEP, which has grown in its contribution to Vertex’s top line over time, continues to run effectively even while we are still implementing improvements to the process,” Cowart stated. “For the remainder of 2011, we expect to continue to exploit our competitive advantage in the combination of used oil aggregation and TCEP operations, while also evaluating potential acquisitions that could enhance our overall competitive positioning within the industry.”
For more information visit www.vertexenergy.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Neoprobe Corp. (NEOP) is “One to Watch”
Neoprobe Corp. has quickly risen to dominate in ILM (intraoperative lymphatic mapping, a minimally invasive lymph node biopsy) cancer surgery markets as the only gamma detection systems developer which simultaneously is refining both its radiotracers and detection hardware. Additionally, the Company has a rapidly growing investigational initiative program focused on innovative radiotracing agents and ACT, or activated cellular therapies, under majority-owned subsidiary, Cira Biosciences, Inc.
Among the detection systems, probes and ancillary devices marketed by NEOP worldwide is a wide variety of wired/wireless options for what has become recognized as a vitally important procedure for cancer patients, where the lymph node tissues can be more easily examined for the spread of cancer. The Neoprobe® GDS gamma detection system is at the heart of the GDS Console developed by the Company as well, which was engineered from the ground up to deliver a zero-calibration, highly-customizable and easy to use all-in-one console, enabling speedy work by healthcare professionals. The GDS Console is able to display multiple radionuclide windows at the same time and is instantly user selectable so multiple users can use it without a problem or having to slow down.
Because solid tumor cancers most often spread via the lymphatic system to other tissues, the ILM procedure has become more and more a de facto standard approach. ILM involves using a tracing agent which is then detected, and because the Company has such a strong portfolio of competencies in detection technology, the tracing agents developed under the investigational initiative are finely tuned to the hardware used for detection, resulting in superior performance.
The Company’s proprietary radioactive tracing agent Lymphoseek® is secured via an exclusive worldwide license agreement with UC San Diego and is ideally suited for ILM. Activated cellular therapy technology has wide ranging applications as well, with deep impact in patient-specific oncology and diseases of the autoimmune system, or with viral infections like HIV/AIDS or hepatitis. The Company’s RIGScan CR system fuses a patented hand-held detection probe and proprietary radio-labeled targeting agents that are cancer-specific, thus allowing surgeons to achieve extremely thorough removal of cancer tissues and better patient results.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Among the detection systems, probes and ancillary devices marketed by NEOP worldwide is a wide variety of wired/wireless options for what has become recognized as a vitally important procedure for cancer patients, where the lymph node tissues can be more easily examined for the spread of cancer. The Neoprobe® GDS gamma detection system is at the heart of the GDS Console developed by the Company as well, which was engineered from the ground up to deliver a zero-calibration, highly-customizable and easy to use all-in-one console, enabling speedy work by healthcare professionals. The GDS Console is able to display multiple radionuclide windows at the same time and is instantly user selectable so multiple users can use it without a problem or having to slow down.
Because solid tumor cancers most often spread via the lymphatic system to other tissues, the ILM procedure has become more and more a de facto standard approach. ILM involves using a tracing agent which is then detected, and because the Company has such a strong portfolio of competencies in detection technology, the tracing agents developed under the investigational initiative are finely tuned to the hardware used for detection, resulting in superior performance.
The Company’s proprietary radioactive tracing agent Lymphoseek® is secured via an exclusive worldwide license agreement with UC San Diego and is ideally suited for ILM. Activated cellular therapy technology has wide ranging applications as well, with deep impact in patient-specific oncology and diseases of the autoimmune system, or with viral infections like HIV/AIDS or hepatitis. The Company’s RIGScan CR system fuses a patented hand-held detection probe and proprietary radio-labeled targeting agents that are cancer-specific, thus allowing surgeons to achieve extremely thorough removal of cancer tissues and better patient results.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Subscribe to:
Posts (Atom)